irinotecan hydrochloride

Campto (UK), Camptosar

Pharmacologic class: Topoisomerase inhibitor

Therapeutic class: Hormonal antineoplastic

Pregnancy risk category D


Inhibits topoisomerase 1 (an enzyme that allows DNA replication) by binding to it. This action prevents religation of DNA strand, which results in breakage of double-stranded DNA and cell death.


Injection: 20 mg/ml in 2-ml and 5-ml vials

Indications and dosages

Metastatic colorectal cancer or recurrence or progression of metastatic colorectal cancer after fluorouracil (5-FU) therapy

Adults: 125 mg/m2 I.V. infused over 90 minutes on days 1, 8, 15, and 22, followed by a 2-week rest; given with leucovorin and 5-FU. Or, 180 mg/m2 I.V. infused over 90 minutes on days 1, 15, and 29 with leucovorin, 5-FU bolus, and 5-FU infusion followed by a 2-week rest. Or as monotherapy, 125 mg/m2 I.V. infused over 90 minutes weekly for 4 weeks, followed by a 2-week rest period; or, 350 mg/m2 I.V. infused over 90 minutes q 3 weeks as long as tolerable. Adjust dosage in increments based on tolerance and age.

Off-label uses

• Most cancers


• Hypersensitivity to drug
• Concurrent atazanavir use
• Pregnancy or breastfeeding


Use cautiously in:
• bone marrow depression, severe diarrhea
• patients undergoing radiation therapy
• elderly patients
• children.


Follow facility policy for handling antineoplastics. If skin contact occurs, wash with soap and water immediately and thoroughly. If mucous membrane contact occurs, flush with water.
• Dilute in dextrose 5% in water or normal saline solution, to a concentration of 0.12 to 1.1 mg/ml.
• Infuse within 6 hours if drug is stored at room temperature or within 24 hours if refrigerated.
• Give single dose by I.V. infusion over 90 minutes.
• Administer antiemetic to ease nausea and vomiting, as needed and prescribed.

Adverse reactions

CNS: insomnia, dizziness, asthenia, headache, akathisia

CV: vasodilation, orthostatic hypotension

EENT: rhinitis

GI: nausea, vomiting, constipation, diarrhea, flatulence, dyspepsia, abdominal pain or enlargement, stomatitis, anorexia

Hematologic: anemia, neutropenia, leukopenia, thrombocytopenia

Hepatic: hepatotoxicity

Metabolic: dehydration

Musculoskeletal: back pain

Respiratory: dyspnea, increased cough

Skin: alopecia, diaphoresis, rash

Other: weight loss, edema, fever, pain, chills, minor infections


Drug-drug.Dexamethasone: increased risk of lymphocytopenia

Diuretics: increased risk of dehydration

Laxatives: increased risk of diarrhea

Other antineoplastics: additive adverse effects

Drug-diagnostic tests.Alkaline phosphatase: increased level

Hemoglobin, neutrophils, white blood cells: decreased values

Patient monitoring

Assess CBC before each infusion. Withhold dose if neutrophil count is below 1,500 cells/mm3.
• Monitor infusion site for extravasation; if it occurs, flush with sterile water and apply ice.
• Assess fluid intake and output. Keep patient well hydrated.
• Monitor oral intake. Evaluate for nausea and vomiting.
• Assess for diarrhea. In severe diarrhea, expect to decrease dosage or withhold dose.
• Institute infection-control protocols to help prevent infection.
• Monitor liver function test results.

Patient teaching

• Inform patient that blood tests will be done before each dose.
• Instruct patient to report pain at infusion site; severe nausea or vomiting; severe, increased, or bloody diarrhea; infection; or injury.

Instruct patient to immediately report unusual tiredness or yellowing of skin or eyes.
• Tell patient that drug increases his risk of infection. Advise him to avoid crowds and other potential infection sources.
• Caution female patient not to breastfeed or become pregnant during therapy. Recommend barrier contraception.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


A brand name for the camptothecin drug IRINOTECAN.
References in periodicals archive ?
Calcium Salt) Eposin Etoposide Injection 20mg/ml Vincristine Vincristine Injection 2mg/2ml in Vial Vincristine Vincristine Injection 10mg/Vial Avastin Bevacizumab Injection 25mg/ml Cisplatin Cisplatin Injection 50mg/Vial Platosin Cisplatin Injection 10mg in 10ml Vial Taxotere Docetaxel Injection 20mg/Vial Glivec Imatinib Capsule 100mg/Capsule Campto Trinotecan Injection 2ml/Vial Paclitaxel Paclitaxel Injection 30mg/5ml in Vial Taxol Paclitaxel Injection 30mg/5ml in Vial Vesanoid Retinoic Acid Capsule 10mg/Capsule Herceptin Trastuzumab Injection 440mg/Vial Tmuran Azathioprine Tablet 50mg/Tablet Cellcept Mycophenolate Tablet 500mg/Tablet Mofetil Neoral Cyclosporin Capsule 25.
FOLFIRINOX: 5-fluorouracil (5-FU, generics), leucovorin (folinic acid, generics), irinotecan (Pfizer's Camptosar/Campto, Daiichi Sankyo's Topotecin, Yakult Honsha's Campto, generics) and oxaliplatin (Sanofi's Eloxatin/Eloxatine, Yakult Honsha's Elplat, generics).
In addition to producing the internationally recognized probiotic beverage, Yakult is also accredited in the pharmaceutical field for its development of Campto Injection (Camptosar), the first-line drug for colorectal cancer in the U.
Earlier Linford, 50, told campto mates he admired her "perky and peachy bum" adding: "I have been fantasising about Kayla's curves.
Sehr trag tropft >> Campto << in mich rein--/ Ach, war der Stoff doch Chiantiwein
Yakult Honsha attributed the revision to favorable sales of anticancer drugs Campto and its cost-cutting efforts as well as foreign exchange gains on local currency denominated-borrowings by subsidiaries abroad.
rights to Campto for Europe and Asia, except Japan, making it a truly global
FOLFIRI: 5-fluorouracil (generics), leucovorin (generics) and irinotecan (Pfizer's Camptosar/Campto, Daiichi Sankyo's Topotecin, Yakult Honsha's Campto, generics).
of commercial rights to Campto (Camptosar in the Americas and Australia) in
FOLFIRI: 5-fluorouracil (5-FU [generics], leucovorin [folinic acid] [generics], irinotecan [Pfizer's Camptosar/Campo, Daiichi Sankyo's Topotecin, Yakult Honsha's Campto, generics])